December 20, 2021
1 min watch
Save
VIDEO: Research ‘to look forward to’ in gene therapy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Matthew M. Heeney, MD, spoke with Healio about presentations on gene therapeutic options for hematologic diseases from ASH Annual Meeting and Exposition.
“Those are all very early stage, but certainly things to look forward to over the next 6 to 12 months,” Heeney, associate chief of hematology and director of the Sickle Cell Program at Dana-Farber/Boston Children’s Cancer and Blood Disorder Center and associate professor at Harvard Medical School, said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Heeney reports consulting for AstraZeneca, Cyclerion Therapeutics, Inc., Forma Therapeutics, Inc., Global Blood Therapeutics, Inc., Micelle BioPharma, Novartis Pharmaceuticals Corporation, Pfizer, and Vertex Pharmaceuticals, Inc./CRISPR Therapeutics; and receiving grant or research support from AstraZeneca, Global Blood Therapeutics and Novartis Pharmaceuticals Corporation.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.